Health

"I'm petrified": her 5-year-old son has a form of childhood dementia, a gene therapy now exists… but it costs almost $4 million

Tate McDaid, from Wales, has Sanfilippo syndrome type A, a rare disease that robs children of speech, walking and memory. In September the US approved the first treatment, Fayuvi. His mother has raised $215,000: barely 5% of what she needs.

By · Published · Updated · Sources

Advertisement
"I'm petrified": her 5-year-old son has a form of childhood dementia, a gene therapy now exists… but it costs almost $4 million

Photo: Matthias Süßen / Wikimedia Commons · CC BY-SA 3.0

A baby's hand resting on an adult's hand; not a person in this story. Reference photo: Matthias Süßen / Wikimedia Commons (CC BY-SA 3.0).

Tammy McDaid spent "months praying" for a treatment to be approved for her son Tate, five, who lives in Swansea, Wales. When it finally happened in September, "I was excited when the treatment initially got approved but then reality hit hard the next day," she told the BBC: the price had been set at £2.95m (about $3.95 million) per child.

Tate was diagnosed at four with Sanfilippo syndrome, a disease so rare that in the UK it affects around 140 children, according to the MPS Society, and which, because of how it progresses, is known as "childhood dementia" or "childhood Alzheimer's".

Advertisement

What Sanfilippo syndrome is

Also called mucopolysaccharidosis type III (MPS III), it is an inherited disease. According to MedlinePlus, from the US National Library of Medicine, children usually seem healthy at birth and problems appear in early childhood: delayed speech, behavior problems such as hyperactivity or trouble sleeping, and over the years the progressive loss of skills already learned, such as talking, walking or eating.

In type A, an enzyme called sulfamidase is missing. Without it, a molecule, heparan sulfate, builds up in cells and slowly damages the brain. Ultragenyx, the company that developed the therapy, estimates a median life expectancy of about 15 years.

His mother describes him as "the happiest little man" who is "blissfully unaware" of his problems. "He doesn't speak, he's never spoken. But his mobility is everything to him and that is why I'm fighting for it," she said.

The therapy that arrived in September

On September 17, 2026, the US FDA approved Fayuvi, the first treatment for children with Sanfilippo type A. It is a one-time intravenous gene therapy that uses a modified, non-infectious virus to deliver a working copy of the SGSH gene to cells, so the body can produce the missing enzyme.

In the study reviewed by the FDA, treated children aged 2 to 5 maintained or improved their cognitive function compared with an untreated historical group. The agency also warns of side effects such as liver changes, nausea, vomiting and fever, and of a risk of thrombotic microangiopathy. It is indicated for children who still have preserved neurodevelopmental function: that is why time matters.

A race against the clock

The condition can progress more rapidly after the age of five, which is why Tammy says "it's really a battle of time" — and Tate turns six this November. She says he is already showing signs of cognitive decline. "The older he gets the less the treatment will work and the more ability he will lose in the process. I feel like we are at a turning point and I'm petrified."

Her campaign has raised more than $215,000, about 5% of the estimated cost. "If a millionaire turned around tomorrow and gave us the money, we'd go to the US straight away," she says.

Ultragenyx told the BBC it cannot give a single estimate of the cost for international patients, that it is pursuing "a global regulatory strategy," and that it encourages families to ask their child's doctor what access routes exist.

If you notice a child losing words or skills they already had, or a significant speech delay with behavior changes, see their pediatrician: early diagnosis of rare diseases opens more options.

Read also: Sobrecarga del cuidador: señales de que cuidar te está agotando · Luz diurna y demencia: lo que dice un estudio

Sources

For information only. It does not replace advice from a health professional. Medical disclaimer

Advertisement